novel therapeutic strategies that would sensitize tumors to oxaliplatin are urgently needed to overcome resistance and toxicity for CRC treatment. The above results corroborated previously published studies. At low treatment dose, colorectal cancer cells show resistance to treatment, while high-dose exert cytotoxic effects on both malignant and normal cells. Thus, combinatorial therapies may be able to offer synergistic anticancer effects with reduced systemic toxicity31. Here, the effects of PL, a natural product, in combination with oxaliplatin in human CRC were assessed. We demonstrated that PL sensitized CRC cells to oxaliplatin-associated growth suppression and apoptosis enhancement. In addition, we demonstrated that PL mediated such effects by inducing ROS-dependent ER stress and mitochondrial dysfunction in CRC.